KR970700505A - 산 활성물질을 갖는 경구투여 형태 및 그의 제조방법(oral dosage form containing colestipol as a carrier and acidic active substances and a process for producing the same) - Google Patents

산 활성물질을 갖는 경구투여 형태 및 그의 제조방법(oral dosage form containing colestipol as a carrier and acidic active substances and a process for producing the same) Download PDF

Info

Publication number
KR970700505A
KR970700505A KR1019960704025A KR19960704025A KR970700505A KR 970700505 A KR970700505 A KR 970700505A KR 1019960704025 A KR1019960704025 A KR 1019960704025A KR 19960704025 A KR19960704025 A KR 19960704025A KR 970700505 A KR970700505 A KR 970700505A
Authority
KR
South Korea
Prior art keywords
dosage form
oral dosage
active substance
cholestipol
oral
Prior art date
Application number
KR1019960704025A
Other languages
English (en)
Other versions
KR100439311B1 (ko
Inventor
발터 뮐러
카르스텐 크레머
Original Assignee
플랭크 베커, 베르너 웨스링
엘티에스 로프만 써라피에-씨스테메 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 플랭크 베커, 베르너 웨스링, 엘티에스 로프만 써라피에-씨스테메 게엠베하 filed Critical 플랭크 베커, 베르너 웨스링
Publication of KR970700505A publication Critical patent/KR970700505A/ko
Application granted granted Critical
Publication of KR100439311B1 publication Critical patent/KR100439311B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

활성물질이 3차 아미노 그룹을 갖는 중합체에 이온적으로 결합한 적어도 하나의 유리 카드복실 그룹을 갖고, 상기 중합체가 콜레스티폴 또는 콜레스티폴 염화수소임을 특징으로 하는 경구투여 형태.

Description

산 활성물질을 갖는 경구투여 형태 및 그의 제조방법(ORAL DOSAGE FORM CONTAINING COSESTIPOL AS A CARRIER AND ACIDIC ACTIVE SUBSTANCES AND A PROCESS FOR PRODUCING THE SAME)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (13)

  1. 활성물질이 3차 아미노 그룹을 갖는 중합체에 이온적으로 결합된 적어도 하나의 유리카르복실 그룹을 갖고, 중합체가 콜레스티폴 또는 콜레스티폴 염화수소임을 특징으로 하는 산 활성물질을 위한 운반체를 갖는 경구투여 형태.
  2. 제1항에 있어서, 활성물질이 비스테로이드성 항류머티즘제의 그룹에 속함을 특징으로 하는 경구투여 형태.
  3. 제2항에 있어서, 활성물질이 안트라닐산, 아세트산 또는 프로피온산의 유도체에 속함을 특징으로 하는 경구투여 형태.
  4. 제1항에 있어서, 활성물질이 라세미체를 나타냄을 특징으로 하는 경구투여 형태.
  5. 제1항에 있어서, 활성물질이 적어도 하나의 키랄중심을 갖고, 거울상이성질체와 관련하여 실질적으로 순수한 형태로 존재함을 특징으로 하는 경구투여 형태.
  6. 제3항에 있어서, 활성물질이 이부프로펜임을 특징으로 하는 경구투여 형태.
  7. 제6항에 있어서, 활성물질이 S(+)-이부프로펜임을 특징으로 하는 경구투여 형태.
  8. 제1항에 있어서, 활성물질이 발프로산임을 특징으로 하는 경구투여 형태.
  9. 제1항에 있어서, 활성물질이 카프토프릴임을 특징으로 하는 경구투여 형태.
  10. 제1항에 있어서, 경구투여 형태가 씹을 수 있는 정제 또는 씹는 껌인것을 특징으로 하는 경구투여 형태.
  11. 제1항에 있어서, 경구투여 형태가 캡슐 또는 정제인것을 특징으로 하는 경구투여 형태.
  12. 활성물질이 액체 용매가 없는 상으로 부터 콜레스티폴 또는 콜레스티폴 염화수소의 염기성 그룹에 결합됨을 특징으로 하는 제1 내지 11항중의 어느 한항 또는 여러항에 따른 경구투여 형태의 제조 방법.
  13. 활성물질이 융점강하를 위해 보조제와 혼합하고, 상기 혼합물로 부터 콜레스티폴 또는 콜레스티폴 염화수소의 염기성 그룹과 결합함을 특징으로 하는 제1항 내지 11항중의 어느 한 항 또는 여러항에 따른 경구투여 형태의 제조 방법.
KR1019960704025A 1994-01-27 1994-12-08 산활성물질을갖는경구투여용제제및그의제조방법 KR100439311B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4402379A DE4402379C2 (de) 1994-01-27 1994-01-27 Orale Arzneiform mit sauren Wirkstoffen und Verfahren zu ihrer Herstellung
DEP4402379.0 1994-01-27
PCT/EP1994/004082 WO1995020394A1 (de) 1994-01-27 1994-12-08 Orale arzneiform enthaltend colestipol als träger mit sauren wirkstoffen und verfahren zu ihrer herstellung

Publications (2)

Publication Number Publication Date
KR970700505A true KR970700505A (ko) 1997-02-12
KR100439311B1 KR100439311B1 (ko) 2005-08-17

Family

ID=6508812

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960704025A KR100439311B1 (ko) 1994-01-27 1994-12-08 산활성물질을갖는경구투여용제제및그의제조방법

Country Status (22)

Country Link
US (1) US5858344A (ko)
EP (1) EP0741574B1 (ko)
JP (1) JP3701971B2 (ko)
KR (1) KR100439311B1 (ko)
AT (1) ATE218371T1 (ko)
AU (1) AU697353B2 (ko)
CA (1) CA2182417C (ko)
CZ (1) CZ291006B6 (ko)
DE (2) DE4402379C2 (ko)
DK (1) DK0741574T3 (ko)
ES (1) ES2177622T3 (ko)
FI (1) FI116880B (ko)
HU (1) HU223317B1 (ko)
IL (1) IL112435A (ko)
MY (1) MY113340A (ko)
NO (1) NO963143L (ko)
NZ (1) NZ277777A (ko)
PL (1) PL315619A1 (ko)
PT (1) PT741574E (ko)
SK (1) SK97296A3 (ko)
WO (1) WO1995020394A1 (ko)
ZA (1) ZA95638B (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403367B1 (en) * 1994-07-07 2002-06-11 Nanogen, Inc. Integrated portable biological detection system
DE19615820A1 (de) * 1996-04-06 1997-10-09 Holger Specht Zahnpflegemittel und Verfahren zu seiner Herstellung
US20030180249A1 (en) * 2002-03-18 2003-09-25 Khanna Satish Chandra Dosage forms for hygroscopic active ingredients
CA2938564C (en) 2006-11-07 2017-04-11 The Procter & Gamble Company Fiber containing compositions and methods of making and using same
US7767248B2 (en) * 2007-02-02 2010-08-03 Overly Iii Harry J Soft chew confectionary with high fiber and sugar content and method for making same
WO2022259848A1 (ja) 2021-06-07 2022-12-15 国立大学法人筑波大学 高分子化バルプロ酸及びその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ191762A (en) * 1978-10-19 1982-09-14 Merck & Co Inc Hypocholesteremic composition containing cholesterol synthesis inhibitor and anion exchange resin
US4221778A (en) * 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
DE3366838D1 (en) * 1982-03-01 1986-11-20 Efamol Ltd Pharmaceutical composition
US4996047A (en) * 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
EP0409432A3 (en) * 1989-07-20 1991-12-11 Warner-Lambert Company Confectionery delivery system
CA2040865C (en) * 1990-05-15 2002-07-23 James L. Bergey Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor

Also Published As

Publication number Publication date
DE4402379A1 (de) 1995-08-03
JP3701971B2 (ja) 2005-10-05
AU1312795A (en) 1995-08-15
DE59410133D1 (de) 2002-07-11
FI962985A (fi) 1996-07-26
CA2182417A1 (en) 1995-08-03
HU9602041D0 (en) 1996-09-30
HU223317B1 (hu) 2004-05-28
PT741574E (pt) 2002-11-29
DK0741574T3 (da) 2002-09-23
FI962985A0 (fi) 1996-07-26
CZ291006B6 (cs) 2002-11-13
ZA95638B (en) 1995-10-25
PL315619A1 (en) 1996-11-25
CZ221396A3 (en) 1997-01-15
IL112435A (en) 1999-01-26
WO1995020394A1 (de) 1995-08-03
AU697353B2 (en) 1998-10-01
JPH09511488A (ja) 1997-11-18
ATE218371T1 (de) 2002-06-15
EP0741574A1 (de) 1996-11-13
IL112435A0 (en) 1995-03-30
NZ277777A (en) 1997-01-29
US5858344A (en) 1999-01-12
DE4402379C2 (de) 1997-09-25
ES2177622T3 (es) 2002-12-16
MY113340A (en) 2002-01-31
FI116880B (fi) 2006-03-31
NO963143D0 (no) 1996-07-26
SK97296A3 (en) 1997-04-09
KR100439311B1 (ko) 2005-08-17
CA2182417C (en) 2007-04-17
NO963143L (no) 1996-09-24
HUT74434A (en) 1996-12-30
EP0741574B1 (de) 2002-06-05

Similar Documents

Publication Publication Date Title
JP4017661B2 (ja) 重合体マトリックス中の作用物質の固溶体の形の作用物質調剤の製法及び該製法により製造された作用物質調剤
ATE227136T1 (de) Mittel zur verstaerkten aufnahme polarer arzneistoffe aus dem kolon
AR065827A2 (es) Formas de dosificacion de liberacion sostenida de sertralina, sales de sertralina, composicion farmaceutica, procedimiento y preparacion y su uso en terapia
EE03292B1 (et) Prootonpumba inhibiitorit sisaldav paljuosaline ravimpreparaat ja selle valmistamise protsess
DE69231359T2 (de) Ibuprofen-salz enthaltende pharmazeutische zusammensetzung
RU94040864A (ru) Конденсированные индольные производные, их получение, фармацевтическая композиция
KR890001533A (ko) 레보도파 메틸 에스테르를 함유하는 제약 조성물, 이들의 제조 및 치료학적 응용
NO304306B1 (no) Nytt arylpropionsyrederivat, farmas°ytisk blanding inneholdende dette, og anvendelse av det nye derivat ved fremstilling av et medikament
KR910007858A (ko) 초기-촉진 및 향상된 진통제로서의 s(+)-이부프로펜-l-아미노산 및 s(+)-이부프로펜-d-아미노산
DE69415018D1 (de) Oralanzuwendende flüssige arzneizubereitung enthaltend 2-(4-isobutylphenyl)propionsäure
KR970700505A (ko) 산 활성물질을 갖는 경구투여 형태 및 그의 제조방법(oral dosage form containing colestipol as a carrier and acidic active substances and a process for producing the same)
KR20080034166A (ko) 감각기관 수용성 이부프로펜 경구 투약 제형 및 동일물의제조 및 사용 방법
ES2090712T3 (es) Medicamento agudo que contiene ibuprofeno y su uso.
JP2005145931A (ja) 非ステロイド系消炎鎮痛剤を含有するテープ剤
KR970069035A (ko) 새로운 진경제와 소염제의 합성 및 제조방법
UA66925C2 (uk) Поліморфні форми кристалічного цитрату азабіцикло[2.2.2]-октан-3-аміну, спосіб їх одержання, фармацевтична композиція та спосіб лікування блювання
DE69800210D1 (de) Wasserfreies Mittel auf Lactulosebasis
RU97104487A (ru) Спазмолитическая композиция
JPS6363614A (ja) イソチペンジル類含有組成物
CN1266685A (zh) 长效复方镇痛药产品制备的技术工艺方法
KR890002239B1 (ko) 인도메타신 연고제의 제조방법
ATE32514T1 (de) 3-(4'-aminobutylamino)-propylamino-bleomycinderivate, verfahren zur ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20110622

Year of fee payment: 8

LAPS Lapse due to unpaid annual fee